Laser Removal of Age (Sun) Spots on Hands

The purpose of this study is to evaluate the safety and efficacy of Cutera Picosecond
Q-Switched Nd:YAG 1064 and/or 532 nm laser in the treatment of benign pigmented lesions on
the hands.

Inclusion Criteria:

- Females or Males, 18 to 60 years of age (inclusive).

- Fitzpatrick Skin Type I - III (Appendix 2).

- Clinical diagnosis of benign solar lentigines of the hands.

- Presence of at least 5 lesions in the treatment area in diameters ranging from 1 to 8
mm.

- Has not used any prescription or over the counter topical creams (e.g., hydroquinone,
and/or retinoids and/or corticosteroids) used in the treatment of pigmentation in the
treatment area within the last 4 weeks.

- Willing to refrain from using any prescription or over the counter topical creams
used for the treatment of pigmentation (e.g., hydroquinone, and/or retinoids and/or
corticosteroids) in the treatment area during the study period.

- Must be able to read, understand and sign the Informed Consent Form.

- Willing and able to adhere to the treatment and follow-up schedule and before and
after treatment care instructions.

- Willing to protect and/or have very limited sun exposure and use an approved
sunscreen of SPF 50 or higher in the treatment area starting up to 4 weeks before the
treatment, every day for the duration of the study, including the follow-up period

- Willing to have digital photographs taken of the treatment area

- Agree not to undergo any other procedure(s) for the treatment of solar lentigines
during the study.

- Post-menopausal or surgically sterilized, or using a medically acceptable form of
birth control at last 3 months prior to enrollment and during the entire course of
the study.

Exclusion Criteria:

- Participation in a study of another device of drug within 6 months prior to
enrollment or during the study.

- Prior treatment of solar lentigines of the hands, e.g., with Q-Switched laser, IPL,
Chemical peel, cryotherapy within 6 months of study participation.

- Having pre-malignant or malignant lesions (e.g., pigmented actinic keratosis, lentigo
maligna [12], lentigo maligna melanoma), or history of a pre-malignant or malignant
lesion in the treatment area.

- Subject shows signs of actinic bronzing or recent tanning in the treatment area, and
unable/unlikely to refrain from tanning during the study.

- Skin abnormalities in the treatment area, e.g., cuts, scrapes, wounds, scars, large
moles.

- Pregnant and/or breastfeeding.

- Having an infection, dermatitis or a rash in the treatment area.

- Significant concurrent illness, such as diabetes mellitus or cardiovascular disease,
e.g., uncontrolled hypertension

- Suffering from coagulation disorders or taking prescription anticoagulation
medications.

- History of keloid scarring, hypertrophic scarring or of abnormal wound healing.

- History of immunosuppression/immune deficiency disorders or currently using
immunosuppression medications.

- History of vitiligo or psoriasis.

- History of connective tissue disease, such as systemic lupus erythematosus or
scleroderma.

- History of seizure disorders due to light.

- Any use of medication that is known to increase sensitivity to light, such as
tetracycline.

- History of radiation to the treatment area or undergoing systemic chemotherapy for
the treatment of cancer.

- History of pigmentary disorders, particularly tendency for hyper- or
hypo-pigmentation.

- Anytime in life, having have used gold therapy (gold salts) for disorders such as
rheumatologic disease or lupus.

- Current smoker or history of smoking within 2 years of study participation.

- As per the Investigator's discretion, any physical or mental condition which might
make it unsafe for the subject to participate in this study.

- History of allergy to topical antibiotics.